BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November 15-19 in Seattle.
- Oral Administration of a Liquid Formulation of BCX7353 Rapidly Provides Sustained Concentrations and Kallikrein Inhibition; Poster P153, Friday, November 16, 3:30 p.m. PT
- Relationship of Target Concentrations with Efficacy: Results from the APeX-1 Study of BCX7353; Poster P157, Friday, November 16, 4:10 p.m. PT
- Pharmacokinetics and Pharmacodynamics of BCX7353, an Oral Plasma Kallikrein Inhibitor, in Healthy Japanese Subjects, Poster P158, Friday, November 16, 4:20 p.m. PT
“The Annual Scientific Meeting of the ACAAI provides a focused opportunity for us to meet with many of the clinical and academic leaders driving continued innovation to improve HAE therapy, and we are excited to, once again, have an important scientific presence at the meeting,” said Dr. William Sheridan, chief medical officer of BioCryst.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral ALK-2 inhibitors for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at .
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that ongoing and future preclinical and clinical development of HAE second generation drug candidates (including ZENITH-1, APeX-2, APeX-S and APeX-J) may not have positive results, may be more expensive or may not move as quickly as planned; that the FDA, EMA or other applicable regulatory agency may not provide regulatory clearances which may result in delay of planned clinical trials or failure to achieve market approval for product candidates. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.
BCRXW
Contact:
John Bluth
